Pre-planned secondary analysis of POISE-3 in 1124 urological surgery patients: tranexamic acid vs placebo did not significantly reduce 30-day composite bleeding (8.1% vs 10.9%; HR 0.73, 0.50–1.07); major bleeding fell (6.1% vs 9.5%); thrombosis similar.
Secondary analysisn = 1,124
Tikkinen et al. Safety and Efficacy of Tranexamic Acid in Urologic Surgery: Results from the International, Randomized, Placebo-Controlled POISE-3 Trial